American Society of Hirudotherapy

HmDestabilase

Hirudinaria manillensis destabilase / i-type lysozyme (Gao 2025) — isopeptidase + lysozyme activity, salivary-gland-upregulated on blood feeding.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 27, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • HmDestabilase16 kDa
Molecular weight (kilodaltons) of HmDestabilase (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Bleeding

Clinical translation limit

HmDestabilase's in vitro isopeptidase / lysozyme activity does NOT establish clinical efficacy. No FDA-approved derivative exists; H. manillensis is not the FDA-cleared K040187 medicinal leech species.

Molecular Profile

Category
Fibrinolytic
Evidence tier
Preclinical
Molecular weight
16,000 Da
Source species
Hirudinaria manillensis
Discovered
2025 · Gao T et al.

Biological Targets

  • → isopeptide bonds in fibrin
  • → bacterial peptidoglycan (lysozyme activity)

Key Citations

  1. Gao T et al. (2025), Protein Expr Purif · PMID 40107525

External Resources

    Related Fibrinolytic Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.